Home   About this service   Get the news  
+32 2 743 34 03

UCB [BE0003739530 / UCB]

UCB Media Room: New UK Campus


[16/10/2020 | 07:04]


=C2=B7 UCB has signed an agreement to acquire a new campus for its UK opera=
tions located in Windlesham, Surrey=C2=A0
=C2=B7 The campus will become home to one of UCB=E2=80=99s three global R&D=
hubs bolstering its cutting-edge R&D, early manufacturing and commercial o=
perations in the UK
=C2=B7 Reinforcing its investment in the UK, this transition to a state-of-=
the-art facility will deliver against UCB=E2=80=99s promise to invest more =
than =C2=A31 billion over five years and support more than 650 high-value j=

Slough, UK and Brussels, Belgium =E2=80=93 16 October 2020 =E2=80=93 UCB ha=
s signed an agreement to acquire a new campus for its UK operations support=
ing cutting-edge research and development, early manufacturing and commerci=
alisation of medicines aiming to transform the lives of people living with =
severe immunological and neurological conditions.

The acquisition of the world-class site in Windlesham, Surrey is anticipate=
d to be completed in November 2020 and reflects UCB=E2=80=99s commitment to=
retain the UK as one of its three global hubs for research and development=
, alongside Belgium and the US.=C2=A0

UCB=E2=80=99s projected investment in the UK, including this site, will be =
more than =C2=A31 billion over five years and the transition to this new fa=
cility will support more than 650 high-value jobs in scientific research, t=
ranslational medicine, clinical development, early manufacturing and commer=
cial roles.

The 47-acre (19 hectare) campus will be acquired from Eli Lilly and Company=
Limited and was formerly its second largest research site worldwide. Follo=
wing completion of the acquisition, the site will undergo state-of-the-art =
refurbishment prior to UCB relocating from its current UK headquarters in S=
lough, Berkshire. This refurbishment will enable successful execution of UC=
B=E2=80=99s research plan to develop innovative treatments for patients inc=
luding gene therapies and translational medicine, as well as development of=
UCB=E2=80=99s world-class antibody discovery platforms.

This new campus in Windlesham reinforces UCB=E2=80=99s conviction in UK lif=
e sciences and its drive in developing innovative treatments for patients w=
ith neurological and immunological conditions. UCB reinvests between 23-28%=
of its revenue into R&D per annum globally, making the company one of the =
most research-intensive companies in Europe. With an extensive network of c=
ollaborations with UK universities, charities and other companies, UCB ende=
avours to further advance scientific research in the UK and deliver the sol=
utions that patients need globally. =C2=A0

Business and Industry Minister Nadhim Zahawi said: =E2=80=9CIt=E2=80=99s fa=
ntastic to see that UCB has re-affirmed its commitment to the UK=E2=80=99s =
world-leading life sciences sector, and I welcome the role this facility wi=
ll play in creating hundreds of high value jobs in the years to come.

=C2=A0=E2=80=9CUCB=E2=80=99s investment demonstrates the huge opportunity f=
or companies investing in UK science and research with government support, =
cementing the UK=E2=80=99s status as a global science superpower.=E2=80=9D
Health Minister Lord Bethell said: =E2=80=9CThis investment is a major vote=
of confidence in our incredible life sciences sector and is further proof =
the UK continues to lead the way in ground-breaking medical research.
=E2=80=9CThis Government will always do everything it can to ensure NHS pat=
ients are the first to benefit from cutting-edge treatments.=C2=A0

=E2=80=9CDeveloping an environment that allows research and development to =
thrive is the best way to allow UK innovation to flourish.=E2=80=9D

Life Science's Champion Professor Sir John Bell said: =E2=80=9CWe have made=
huge progress since the Industrial Strategy was published in 2017 towards =
making the UK a global hub for life sciences.

=E2=80=9CToday=E2=80=99s announcement from UCB is a further illustration of=
the research, health and economic benefits that can be achieved through in=
vestment in the UK=E2=80=99s life sciences sector.=E2=80=9D

Jean-Christophe Tellier, Chief Executive Officer at UCB said: =E2=80=9CWe h=
ave a strong track record of discovering medicines in the UK which go on to=
make a difference to the lives of patients worldwide. I am delighted to ha=
ve signed an agreement to secure this new campus for our UK hub, from which=
our scientists will be able to continue to develop their extensive collabo=
rations with some of the most innovative universities, bio-techs and medica=
l research charities, bringing even greater benefit for patients.

=E2=80=9CThis new UK site will not only support our ambitions for future dr=
ug discovery but will be well-placed to enable us to achieve our 2030 globa=
l sustainability goals and provides an environment which supports the physi=
cal and mental wellbeing of our people =E2=80=93 essential to helping us th=

Worldwide UCB=E2=80=99s global footprint has been strengthened significantl=
y in recent times allowing the company to meet its ambitions for patient-fo=
cused medicines of the future. Alongside the new UK site, these include acq=
uisition of Ra Pharma enhancing UCB=E2=80=99s innovation capabilities in th=
e US and substantial investments in the Belgian Braine l=E2=80=99Alleud cam=


Notes to Editors

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With 7 500 people in approxima=
tely 40 countries, the company generated revenue of =E2=82=AC 4.9 billion i=
n 2019. UCB is listed on Euronext Brussels (symbol: UCB).

Contact UCB:=C2=A0
UK Communications Karen Borrer karen.borrer@ucb.co.uk +44 (0)1753 713006 +4=
4 (0) 7775 003538
Corporate Communications Laurent Schots Laurent.schots@ucb.com +32 (0)2 559=
92 64=C2=A0=C2=A0
Investor Relations Antje Witte antje.witte@ucb.com =C2=A0+32 (0)2 559 94 14=
Investor Relations Isabelle Ghellynck, isabelle.ghellynck@ucb.com +32 (0)2 =
559 9588=C2=A0
About the Windlesham site

The site in Windlesham, Surrey is a 47-acre (19 hectare), internationally r=
ecognised life sciences research and development campus. Currently owned by=
Eli Lilly and Company Limited, following completion of the acquisition by =
UCB, the site will undergo extensive refurbishment before relocation by UCB=
from its current location in Slough, Berkshire.

Forward looking statements - UCB
This press release contains forward-looking statements based on current pla=
ns, estimates and beliefs of management. All statements, other than stateme=
nts of historical fact, are statements that could be deemed forward-looking=
statements, including estimates of revenues, operating margins, capital ex=
penditures, cash, other financial information, expected legal, political, r=
egulatory or clinical results and other such estimates and results.=C2=A0
By their nature, such forward-looking statements are not guarantees of futu=
re performance and are subject to risks, uncertainties and assumptions whic=
h could cause actual results to differ materially from those that may be im=
plied by such forward-looking statements contained in this press release. I=
mportant factors that could result in such differences include: changes in =
general economic, business and competitive conditions, the inability to obt=
ain necessary regulatory approvals or to obtain them on acceptable terms, c=
osts associated with research and development, changes in the prospects for=
products in the pipeline or under development by UCB, effects of future ju=
dicial decisions or governmental investigations, product liability claims, =
challenges to patent protection for products or product candidates, changes=
in laws or regulations, exchange rate fluctuations, changes or uncertainti=
es in tax laws or the administration of such laws and hiring and retention =
of its employees.=C2=A0
UCB is providing this information as of the date of this press release and =
expressly disclaims any duty to update any information contained in this pr=
ess release, either to confirm the actual results or to report a change in =
its expectations.
There is no guarantee that new product candidates in the pipeline will prog=
ress to product approval or that new indications for existing products will=
be developed and approved. Products or potential products which are the su=
bject of partnerships, joint ventures or licensing collaborations may be su=
bject to differences between the partners. Also, UCB or others could discov=
er safety, side effects or manufacturing problems with its products after t=
hey are marketed. Moreover, sales may be impacted by international and dome=
stic trends toward managed care and health care cost containment and the re=
imbursement policies imposed by third-party payers as well as legislation a=
ffecting biopharmaceutical pricing and reimbursement.

UCB UK New Site Announcement Press Release Final (https://u7061146.ct.sendg=
If you would rather not receive future communications from UCB SA, please g=
o to https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jAT=
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=